Skip To Main Content
Alan Wigg on Muck Rack

Alan Wigg

As seen in: Color Research & Application, Frontline Gastroenterology, EClinicalMedicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Alan Wigg’s profile

Articles by Alan Wigg

Cross-sectional study of the prevalence of chronic liver disease risk factors and liver fibrosis in a remotely living Indigenous Australian population

|
By Alan Wigg, Sumudu Narayana, Michael Nugent, Arlene Ackland
| Frontline Gastroenterology Verified
Abstract Objectives Remotely living Indigenous Australians have a disproportionate mortality from cirrhosis and hepatocellular cancer (HCC). However, there are no local population studies examining the prevalence of chronic liver disease (CLD) in remote communities. The main aims of this study were therefore to study a remote Indigenous population to determine the prevalence of CLD risk factors and the prevalence of significant fibrosis as defined by an Fibrosis-4 (FIB-4) score of ≥2.67.
Open in Who Shared Issue with article?

Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia

|
By Alan Wigg, Sumudu Narayana, Gunter Hartel, Linda Medlin
| EClinicalMedicine Verified
Abstract Background Liver disease and hepatocellular carcinoma (HCC) are important contributors to the mortality gap between Indigenous and non-Indigenous Australians. However, there is a lack of population based high quality data assessing the differences in HCC epidemiology and outcomes according to Indigenous status. The aim of this study was therefore to perform a large epidemiological study of HCC investigating differences between Indigenous and non-Indigenous Australians with HCC.
Open in Who Shared Issue with article?

Real‐world outcomes of unrestricted direct‐acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience

|
By Kate Muller, James Haridy, Alan Wigg, Jeyamani Ramachandran
| Color Research & Application Verified
In March 2016, the Australian government offered unrestricted access to direct‐acting antiviral (DAA) therapy for chronic hepatitis C (HCV) to the entire population. This included prescription by any medical practitioner in consultation with specialists until sufficient experience was attained. We sought to determine the outcomes and experience over the first twelve‐months for the entire state of South Australia.
Open in Who Shared Issue with article?
Show More